01/21/2024
SIGN ON LETTER opposing INDUSTRY friendly Medicare Advantage letter.......... Please sign on
January 17, 2024
Dear health justice activist,
We’ve been waiting for it and the time has come—an industry-friendly Medicare Advantage letter has officially launched in the Senate, circulated by Sens. Catherine Cortez Masto (D-NV), Tim Scott (R-SC), Gary Peters (D-MI), and Shelley Moore Capito (R-WV); you can find PNHP’s response to their letter HERE.
The deadline for signing this letter is one week from today—Wednesday, Jan. 24. It’s our job as activists to let our senators know that we do NOT want them to sign on. We encourage you to take a few minutes today to make sure your senators know where you stand on the so-called “Medicare Advantage” program.
Email your senators now!
You can also call your senators’ offices by dialing the U.S. Capitol Switchboard at (202) 224-3121. A suggested script is below, but feel free to adjust it:
Hello, my name is [YOUR NAME HERE] and I’m a constituent of Senator [NAME]. I’m reaching out about the Medicare Advantage program. Currently, there is a letter circulating in the Senate led by Senators Cortez Masto, Scott, Peters, and Capito praising the program and asking for “stability,” which really means no changes that might protect seniors and people with disabilities.
I’m calling to urge the Senator to NOT sign on to this letter.
The Medicare Advantage program has a record of harming patients by delaying and denying care, and by restricting our choice of doctor. Insurance corporations have also been caught overcharging taxpayers by up to 140 billion dollars per year. Rather than uncritically promoting Medicare Advantage, we need Congress to reappraise the program and hold health insurers accountable for their plans’ shortcomings. Thank you for your time.
Thank YOU for taking action to fight back against corporate profiteering in Medicare!
In solidarity,
PNHP Organizing Team
Physicians for a National Health Program
29 E Madison St Ste 1412 | Chicago, Illinois 60602
312-782-6006 | [email protected]
Follow Us
Having trouble viewing this email? View it in your web browser
